Entity

Time filter

Source Type

Shelton, WA, United States

Abrams D.I.,University of California at San Francisco | Couey P.,University of California at San Francisco | Shade S.B.,University of California at San Francisco | Kelly M.E.,University of California at San Francisco | And 2 more authors.
BMC Complementary and Alternative Medicine | Year: 2011

Background: Antiretroviral treatment (ART) regimens in HIV patients commonly cause significant lipid elevations, including increases in both triglycerides and cholesterol. Standard treatments for hypercholesterolemia include the HMG CoA reductase inhibitors, or "statins." Because many ART agents and statins share a common metabolic pathway that uses the cytochrome P450 enzyme system, coadministration of ART with statins could increase statin plasma levels significantly. The oyster mushroom, Pleurotus ostreatus, has been shown in animal models to decrease lipid levels - a finding that has been supported by preliminary data in a small human trial.Methods: To assess the safety and efficacy of P. ostreatus in patients with HIV and ART-induced hyperlipidemia, a single-arm, open-label, proof-of-concept study of 8 weeks' duration with a target enrollment of 20 subjects was conducted. Study patients with ART-induced elevated non-HDL cholesterol levels (> 160 mg/dL) were enrolled. Participants received packets of freeze-dried P. ostreatus (15 gm/day) to be administered orally for the 8 week trial period. Lipid levels were drawn every two weeks to assess efficacy. Safety assessments included self-reported incidence of muscle aches and measurement of liver and muscle enzymes. Mean within-person change in lipid levels were estimated using generalized estimating equations to account for repeated observations on individuals. A 30 mg/dL decrease in non-HDL cholesterol was deemed clinically significant.Results: 126 patients were screened to enroll 25, of which 20 completed the 8-week study. The mean age was 46.4 years (36-60). Patients had a mean 13.7 yrs of HIV infection. Mean non-HDL cholesterol was 204.5 mg/dL at day 0 and 200.2 mg/dL at day 56 (mean within-person change = -1.70; 95% confidence interval (CI) = -17.4, 14.0). HDL cholesterol levels increased from 37.8 mg/dL at day 0 to 40.4 mg/dL on day 56 (mean within-person change = 2.6; 95% CI = -0.1, 5.2). Triglycerides dropped from 336.4 mg/dL on day 0 to 273.4 mg/dL on day 56 (mean within-person change = -63.0; 95% CI = -120.9, -5.1). Only 3 individuals achieved a sustained clinically significant (30 mg/dL) decline in non-HDL cholesterol after 8 weeks of therapy. There were no adverse experiences reported other than patients' distaste for the preparation. Liver function tests and muscle enzymes were not affected by the 8 weeks of treatment.Conclusions: Pleurotus ostreatus as administered in this experiment did not lower non-HDL cholesterol in HIV patients with ART-induced hypercholesterolemia. Small changes in HDL and triglycerides were not of a clinical magnitude to warrant further study.Trial Registration: clinicaltrials.gov Identifier: NCT00069524. © 2011 Abrams et al; licensee BioMed Central Ltd. Source


Fungi Perfecti, LLC | Entity website


Fungi Perfecti, LLC | Entity website


Fungi Perfecti, LLC | Entity website

Indoor Growing Fungi Perfecti offers a wide variety of Certified Organic Indoor Mushroom Patches. Each kit comes with illustrated instructions and is guaranteed to produce ...


Fungi Perfecti, LLC | Entity website

Host Defense MycoBotanicals MycoBotanicals are the new Host Defense formulas featuring carefully-selected herbs to complement specific mushrooms for a powerful impact on targeted body systems. Only organically-grown herbs accompany Host Defense Organic Mushrooms, delivering the perfect blend from both kingdoms in one convenient formula ...

Discover hidden collaborations